Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2017-10-02

FDA Approved: ALUNBRIG — Supplemental Application (Takeda Pharmaceuticals America, Inc.)

View source ↗

Summary

The FDA approved a supplemental application for ALUNBRIG (brigatinib) from Takeda, resulting in updates to its labeling.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Alunbrig (Brigatinib)

Snippet

SUPPL AP for ALUNBRIG (BRIGATINIB)